Ignite Creation Date:
2025-12-25 @ 2:42 AM
Ignite Modification Date:
2026-02-25 @ 9:10 PM
Study NCT ID:
NCT05396833
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-26
First Post:
2022-05-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
Sponsor:
EMD Serono Research & Development Institute, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic or Locally Advanced Unresectable Solid Tumors | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | ATR inhibitor | View |
| None | ATM inhibitor | View |
| None | Immunotherapy | View |
| None | Tuvusertib (M1774) | View |
| None | Lartesertib (M4076) | View |
| None | Avelumab | View |
| None | Metastatic or Locally Advanced Unresectable Solid Tumors | View |
| None | DNA Damage Response Inhibitor | View |
| None | Immune Checkpoint Inhibitor | View |